News
1d
GlobalData on MSNNovo Nordisk defeated in Wegovy patent dispute by ViatrisThe Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...
1don MSN
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...
2d
Money Talks News on MSNYour Wegovy Access Just Changed: What Patients Need to Know NowNovo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...
Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results